Filter News

Trubion Pharmaceuticals Inc. Announces Upcoming Presentation at the 2007 American Society of Hematology Annual Meeting

Published: Dec 07, 2007

SEATTLE, Dec. 6 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. today announced that certain data regarding the company's TRU-016 (CD37 SMIP(TM)) program will be presented at the 49th annual meeting of the American Society of Hematology (ASH). The meeting will be held Dec. 8-11, 2007, at the Georgia World Congress Center in Atlanta.

Title:

[801] Role of CD37 SMIP, a Novel Engineered Small Modular Immunopharmaceutical, in the Treatment of CLL

Authors:

Rosa Lapalombella, Xiaobin B. Zhao, Peter R. Baum, Jeffrey A. Ledbetter, Natarajan Muthusamy, John C. Byrd, Division of Hematology and Oncology, Department of Internal Medicine; Division of Pharmaceutics, The Ohio State University, Columbus, Ohio, USA; Trubion Pharmaceuticals, Seattle, Wash., USA

About Trubion

Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The company's product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP custom drug assembly technology. In December 2005, the company entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including TRU-015. In addition, Trubion's TRU-016 program targets CD37, an antigen present on B cells, for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma. The company filed an IND for TRU-016 in the fourth quarter of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program. For additional information visit http://www.trubion.com.

jdenike@trubion.comjmoede@waggeneredstrom.com

TRBN-G

CONTACT: Jim DeNike, Senior Director, Corporate Communications of Trubion
Pharmaceuticals Inc., +1-206-838-0500, jdenike@trubion.com; or Jenny Moede,
Senior Vice President of Waggener Edstrom Worldwide Healthcare,
+1-503-443-7000, jmoede@waggeneredstrom.com, for Trubion Pharmaceuticals
Inc.

Web site: http://www.trubion.com/

Back to news